In the current study, the benefits and potential mechanisms of GPER1 in NASH progression were investigated, and we certified that the hepatic steatosis, inflammation, fibrosis, or insulin resistance in mouse NAFLD/NASH models were exacerbated by hepatocyte-specific GPER1 knockout but obviously mitigated by hepatic GPER1 activation. The gene discussed is GPER1; the disease is Hepatic steatosis.